Chapter 1. Market Definition
                   
Chapter 2. Executive Summary
                    2.1. Market Outlook
                    2.2. Competitive Insights

Chapter 3. Market Dynamics
                    3.1. Drivers

                    3.2. Restraints

Chapter 4. Market Analysis
                        4.1. Porter’s Analysis
                            4.1.1. Supplier power
                            4.1.2. Buyer power
                            4.1.3. Threat of new entrant
                            4.1.4. Competitive rivalry

                        4.2. PESTEL Analysis

Chapter 5. Pricing Analysis

Chapter 6. Pipeline Analysis, By Phase

Chapter 7. Regulatory Framework
                       
Chapter 8. Market Segmentation : Market Estimates and Forecasts

8.1.  Global Multiple Myeloma Drugs Market Estimates and Forecasts, by Therapy, Revenue (USD Million)

8.1.1. Immunomodulatory Drugs: Market estimates and forecasts, 2018 to 2030 (USD Million)

8.1.2. Monoclonal antibodies: Market estimates and forecasts, 2018 to 2030 (USD Million)

8.1.3. Proteasome inhibitors: Market estimates and forecasts, 2018 to 2030 (USD Million)

8.1.4. Bispecific antibodies: Market estimates and forecasts, 2018 to 2030 (USD Million)

8.1.5. (CAR) T-cell therapy: Market estimates and forecasts, 2018 to 2030 (USD Million)

8.1.6. Selective inhibitors: Market estimates and forecasts, 2018 to 2030 (USD Million)

8.1.7. Antibody-drug conjugates: Market estimates and forecasts, 2018 to 2030 (USD Million)

8.1.8. Chemotherapy drugs: Market estimates and forecasts, 2018 to 2030 (USD Million)

8.1.9. Corticosteroids: Market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 9. Competitive Landscape
                    9.1. Vendor market share analysis, 2024
                    9.2. Brand Analysis (Top Brands)
                    9.3. Competitive Dashboard

                    9.4 Strategy Mapping

9.4.1. New Product Launch

9.4.2. Collaborations, Mergers & Acquisitions

                     9.5 Vendor Profiles

                        9.5.1.  Johnson & Johnson
                            9.5.1.1. Company overview
                            9.5.1.2. Financial performance
                            9.5.1.3. Product portfolio
                            9.5.1.4. Strategic initiatives

                       9.5.2. Bristol-Myers Squibb Company
                            9.5.2.1. Company overview
                            9.5.2.2. Financial performance
                            9.5.2.3. Product portfolio
                            9.5.2.4. Strategic initiatives

                        9.5.3. TAKEDA
                            9.5.3.1. Company overview
                            9.5.3.2. Financial performance
                            9.5.3.3. Product portfolio
                            9.5.3.4. Strategic initiatives

                        9.5.4. Sanofi
                            9.5.4.1. Company overview
                            9.5.4.2. Financial performance
                            9.5.4.3. Product portfolio
                            9.5.4.4. Strategic initiatives

                        9.5.5. Amgen
                            9.5.5.1. Company overview
                            9.5.5.2. Financial performance
                            9.5.5.3. Product portfolio
                            9.5.5.4. Strategic initiatives

                        9.5.6. Pfizer
                            9.5.6.1. Company overview
                            9.5.6.2. Financial performance
                            9.5.6.3. Product portfolio
                            9.5.6.4. Strategic initiatives

                        9.5.7. GlaxoSmithKline (GSK)

                            9.5.7.1. Company overview
                            9.5.7.2. Financial performance
                            9.5.7.3. Product portfolio
                            9.5.7.4. Strategic initiatives

                        9.5.8. Karyopharm

                            9.5.8.1. Company overview
                            9.5.8.2. Financial performance
                            9.5.8.3. Product portfolio
                            9.5.8.4. Strategic initiatives

Chapter 10. Methodology and Scope

                    10.1. Research Methodology

                    10.2. Information Procurement - Sources
                        10.2.1. Secondary sources
                        10.2.2. Primary research
                        10.2.3. Details of primary research

                    10.3. Data analysis models

                    10.4. Market Formulation & Validation

                    10.5. Questionnaire

·       By Therapy (Immunomodulatory Drugs, Monoclonal antibodies, Proteasome inhibitors, Bispecific antibodies, (CAR) T-cell therapy, Selective inhibitors, Antibody-drug conjugates, Chemotherapy drugs, Corticosteroids) (Revenue, USD Million, 2018 - 2030)

1.      Johnson & Johnson – DARZALEX, TECVAYLI, TALVEY, CARVYKTI, VELCADE

2.      Bristol-Myers Squibb Company – REVLIMID, POMALYST, EMPLICITI, ABECMA

3.      TAKEDA – NINLARO, VELCADE

4.      Sanofi – SARCLISA

5.      Amgen – KYPROLIS

6.      Pfizer – ELREXFIO

7.      GlaxoSmithKline (GSK) - BLENREP

8.      Karyopharm – XPOVIO